Estimated costs of managing treatment-related adverse events (TRAEs) of nivolumab (nivo) and docetaxel (doc) in the CheckMate 017 and CheckMate 057 phase III non-small cell lung cancer (NSCLC) trials

被引：1
|
作者：
Venkatachalam, Meena
Stenehjem, David D.
Pietri, Guilhem
Penrod, John R.
Korytowsky, Beata
机构：
[1] Parexel, Waltham, MA USA
[2] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA
[3] Bristol Myers Squibb, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.6617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6617
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).
    Paz-Ares, Luis
    Horn, Leora
    Borghaei, Hossein
    Spigel, David R.
    Steins, Martin
    Ready, Neal
    Chow, Laura Quan Man
    Vokes, Everett E.
    Felip, Enriqueta
    Holgado, Esther
    Barlesi, Fabrice
    Kohlhaeufl, Martin
    Rodriguez, Oscar
    Burgio, Marco Angelo
    Fayette, Jerome
    Gettinger, Scott N.
    Harbison, Christopher
    Dorange, Cecile
    Finckenstein, Friedrich Graf
    Brahmer, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)
    Paz-Ares, Luis
    Horn, Leora
    Borghaei, Hossein
    Spigel, David R.
    Steins, Martin
    Ready, Neal
    Chow, Laura Quan Man
    Vokes, Everett E.
    Felip, Enriqueta
    Holgado, Esther
    Barlesi, Fabrice
    Kohlhaeufl, Martin
    Rodriguez, Oscar
    Burgio, Marco Angelo
    Fayette, Jerome
    Gettinger, Scott N.
    Harbison, Christopher
    Dorange, Cecile
    Finckenstein, Friedrich Graf
    Brahmer, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
  • [3] Phase 3, Randomized Trial (CheckMate 017) of Nivolumab (NIVO) vs Docetaxel in Advanced Squamous (SQ) Cell Non-Small Cell Lung Cancer (NSCLC)
    Reckamp, Karen
    Brahmer, Julie R.
    Spigel, David R.
    Rizvi, Naiyer A.
    Poddubskaya, Elena
    West, Howard
    Eberhardt, Wilfried E. E.
    Baas, Paul
    Antonia, Scott J.
    Pluzanski, Adam
    Vokes, Everett
    Holgado, Esther
    Waterhouse, David
    Ready, Neal
    Gainor, Justin F.
    Aren Frontera, Osvaldo
    Horn, Leora
    Paz-Ares, Luis
    Li, Ang
    Lynch, Mark
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S174 - S175
  • [4] PHASE 3, RANDOMIZED TRIAL (CHECKMATE 017) OF NIVOLUMAB (NIVO) VS DOCETAXEL IN ADVANCED SQUAMOUS (SQ) CELL NON-SMALL CELL LUNG CANCER (NSCLC)
    Rechamp, Karen
    Spigel, David R.
    Rizvi, Naiyer
    Poddubskaya, Elena
    West, Howard
    Eberhardt, Wilfried
    Baas, Paul
    Antonia, Scott J.
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David
    Reddy, Neal
    Gainor, Justin
    Frontera, Osvaldo Aren
    Horn, Leora
    Paz-Ares, Luis
    Zhu, Jin
    Lynch, Mark
    Brahmer, Julie
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 130 - 130
  • [5] Impact of baseline serum cytokines on survival in patients (pts) with advanced squamous (SO) non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) or docetaxel (doc): Exploratory analyses from CheckMate 063 and CheckMate 017
    Farsaci, Benedetto
    Geese, William J.
    Desai, Kaushal D.
    Jin, Chelsea
    Antonia, Scott J.
    Lena, Herve
    Horn, Leora
    Planchard, David
    Reckamp, Karen L.
    Stinchcombe, Thomas E.
    Gettinger, Scott
    Borghaei, Hossein
    Hellmann, Matthew D.
    Harbison, Christopher
    Xu, Dong
    Blackwood-Chirchir, M. Anne
    Rizvi, Naiyer
    CANCER RESEARCH, 2016, 76
  • [6] Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
    Borghaei, Hossein
    Gettinger, Scott
    Vokes, Everett E.
    Chow, Laura Q. M.
    Burgio, Marco Angelo
    Carpeno, Javier de Castro
    Pluzanski, Adam
    Arrieta, Oscar
    Frontera, Osvaldo Aren
    Chiari, Rita
    Butts, Charles
    Wojcik-Tomaszewska, Joanna
    Coudert, Bruno
    Garassino, Marina Chiara
    Ready, Neal
    Felip, Enriqueta
    Garcia, Miriam Alonso
    Waterhouse, David
    Domine, Manuel
    Barlesi, Fabrice
    Antonia, Scott
    Wohlleber, Markus
    Gerber, David E.
    Czyzewicz, Grzegorz
    Spigel, David R.
    Crino, Lucio
    Eberhardt, Wilfried Enst Erich
    Li, Ang
    Marimuthu, Sathiya
    Brahmer, Julie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (07) : 723 - +
  • [7] Advanced non-small Cell Lung Carcinoma (NSCLC) CheckMate-017 and-057 in the Update: Survival Advantage with Nivolumab vs. Docetaxel is still confirmed
    Sankawa, Yuri
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (12) : 834 - 835
  • [8] Phase 3, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs)
    Horn, L.
    Brahmer, J.
    Reck, M.
    Borghaei, H.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M. J.
    Burgio, M. A.
    Fayette, J.
    Gettinger, S. N.
    Harbison, C. T.
    Li, A.
    Finckenstein, F. G.
    Paz-Ares, L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S599 - S599
  • [9] Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
    Felip Font, E.
    Gettinger, S. N.
    Burgio, M. A.
    Antonia, S. J.
    Holgado, E.
    Spigel, D. R.
    Arrieta, O.
    Domine Gomez, M.
    Aren Frontera, O.
    Brahmer, J.
    Chow, L. Q.
    Crino, L.
    Butts, C.
    Coudert, B.
    Horn, L.
    Steins, M.
    Geese, W. J.
    Li, A.
    Healey, D.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Three-Year Follow-Up From checkMate 017/057: Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
    Felip, Enriqueta
    Gettinger, Scott
    Burgio, Marco Angelo
    Antonia, Scott J.
    Holgado, Esther
    Spigel, David
    Arrieta, Oscar
    Domine, Manuel
    Aren Frontera, Osvaldo
    Brahmer, Julie
    Chow, Laura Q.
    Crino, Lucio
    Butts, Charles
    Coudert, Bruno
    Horn, Leora
    Steins, Martin
    Geese, William J.
    Li, Ang
    Healey, Diane
    Vokes, Everett E.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 142 - 143
12345